Ubs Group Ag Incyte Corp Call Options Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $198,504 - $239,490	-2,700 Reduced 0.62%	435,000 $37 Million
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $171,612 - $238,059	2,700 Added 0.62%	437,700 $37.6 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $13.7 Million - $16.4 Million	235,000 Added 117.5%	435,000 $27.7 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $4.44 Million - $6.13 Million	-73,000 Reduced 26.74%	200,000 $13.4 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $6.06 Million - $7.37 Million	73,000 Added 36.5%	273,000 $22.7 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $21.8 Million - $27.7 Million	200,000	200,000 $23.3 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.